Bioprox Healthcare holds a prominent position in the industrial landscape of Maine-et-Loire in France, with its rapidly expanding biotech facility. Thanks to its state-of-the-art equipment, the company is able to produce a wide range of probiotics and postbiotics tailored to specific requirements and to deliver high-quality services to its clients.
A research and development laboratory specialised in microbiology, focused on the development of bespoke and next-generation strains, customised analyses and genome characterisation among others.
A factory equipped with several high-capacity fermenters and multiple advanced freeze-drying systems, designed for the efficient production and stabilization of bioproducts.
By providing a controlled, scalable and collaborative environment, Bioprox Healthcare’s unique pilot facility is crucial for the successful transition of new processes and technologies from the laboratory to commercial production.
Bioprox’s services encompass the entire production process, ensuring high-quality outcomes at every stage:
Fermentation using high-capacity and cutting-edge fermenters to cultivate microorganisms under optimal conditions
Separation of the biomass by centrifugation
Freeze-drying output
Blending single or multi-strains blends with excipients and/or other active ingredients
Packaging
Our integrated approach guarantees that each product benefits from our extensive expertise, delivering superior results from concept to commercialisation.
"With my colleagues, engineers and technicians, we leverage our scientific and technical expertise to develop innovative solutions. With decades of experience in scaling up and industrial operation, we transform laboratory processes into viable industrial processes at our biotechnology plant”.
To support Bioprox's growth, a major expansion of its production site is underway from 2023. By increasing its industrial capacities twofold, the French company will significantly strengthen its position in both national and international markets. This is the third major expansion the plant has undergone since its foundation in 1975.
1975
1985
1998
2003
2009
2011
2016
2019
2021
2023
1975
Acquisition of the Noyant dairy factory
and its conversion into an industrial site, modernising and transferring the Bioprox factory from Fourcarmont (Normandy) to Noyant.
1985
Construction of the fermentation and freeze-drying workshop
producing lactic acid bacteria, ripening cultures, and oenological yeasts.
1998
Initiation of export.
2003
First significant increase
in production capacities to meet growing demands.
2009
Relocation of the R&D centre
from Château-Renault to the Noyant site to enhance industrial transfer activities.
2011
New business unit dedicated to probiotics
2016
Creation of an industrial workshop within the factory
for the new activity of soil microorganism biosolutions with Cybèle Agrocare.
2019
Second expansion of the manufacturing site
with an increase of the R&D centre to 1000 m².
2021
Obtaining FSSC 22000 certification & Ecovadis silver medal.
2023
Third modernisation and investment in new technologies
Launch of two major projects to advance the Bioprox production facility. This strategic expansion involves not only increasing industrial fermentation capacities twofold but also a profound transformation of production processes through the integration of the latest technologies.
"The manufacturing site in Noyant is currently undergoing significant expansion.""This initiative is pivotal as we aim to support the average annual growth of 30% witnessed over the past decade. Indeed, the modernisation not only enhances our operational robustness but also underscores our commitment to meeting the growing demand and requirements to a “T”. Bioprox Healthcare has always been able to rely on knowledge of industrial processes and the properties of cultivated microorganisms. We do have this level of technicity thanks to our sister company, Bioprox Cultures, a French specialist in large-scale industrial fermentation since 1975. The company has developed a solid industrial production activity for over 50 bacterial species as well as high-quality consulting services. This expertise is fundamental to enhancing the effectiveness of probiotics in our clients' future products, solidifying Bioprox's position in the competitive landscape of probiotics’ sector."
Eric De Mol, Bioprox Healthcare’s General Manager — January 2024
We ensure high quality processes and facility operations. We adhere to current regulatory standards and promote a quality compliance culture:
Regarding our Corporate Social Responsibility (CSR), Bioprox Healthcare is awarded the Ecovadis Silver certification. We aim to integrate our social and environmental concerns into all our activities.
l Certified ISO 9001 manufacturing site
l Certified FSSC 22000 manufacturing site
l Halal & Kosher productions
l Allergen free
l Non-GMO
Interested by our services ?
S.svg){kind=logo}
